Select Publications
Journal articles
2024, 'Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia', The Lancet Regional Health - Western Pacific, 51, http://dx.doi.org/10.1016/j.lanwpc.2024.101185
,2024, 'Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population-based study', Drug and Alcohol Review, 43, pp. 1080 - 1092, http://dx.doi.org/10.1111/dar.13688
,2024, 'Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs', International Journal of Drug Policy, 128, http://dx.doi.org/10.1016/j.drugpo.2024.104468
,2024, 'Sex and gender differences in hepatitis C virus risk, prevention, and cascade of care in people who inject drugs: systematic review and meta-analysis', eClinicalMedicine, 72, http://dx.doi.org/10.1016/j.eclinm.2024.102596
,2024, 'Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study', International Journal of Drug Policy, 127, http://dx.doi.org/10.1016/j.drugpo.2024.104394
,2024, 'Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study', Drug and Alcohol Review, 43, pp. 1019 - 1028, http://dx.doi.org/10.1111/dar.13828
,2024, 'Corrigendum to “Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales” [JHEP Reports 4 (2022)] (JHEP Reports (2022) 4(10), (S2589555922001240), (10.1016/j.jhepr.2022.100552))', JHEP Reports, 6, http://dx.doi.org/10.1016/j.jhepr.2024.101022
,2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013
,2023, 'Cascade of care among people with hepatitis B in New South Wales, Australia', Journal of Viral Hepatitis, 30, pp. 926 - 938, http://dx.doi.org/10.1111/jvh.13881
,2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632, http://dx.doi.org/10.1111/dar.13723
,2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', The Lancet Regional Health - Western Pacific, 36, http://dx.doi.org/10.1016/j.lanwpc.2023.100750
,2023, 'Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets', Journal of Viral Hepatitis, 30, pp. 520 - 529, http://dx.doi.org/10.1111/jvh.13824
,2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791
,2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469
,2023, 'Cascade of care among people with an HBV notification in New South Wales, Australia, including diagnosis, specialist assessment, and treatment uptake', Journal of Hepatology, 78, pp. S910 - S910, http://dx.doi.org/10.1016/s0168-8278(23)02932-x
,2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876
,2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463
,2022, 'Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales', JHEP Reports, 4, http://dx.doi.org/10.1016/j.jhepr.2022.100552
,2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
,2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
,2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496
,2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, 235, http://dx.doi.org/10.1016/j.drugalcdep.2022.109438
,2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, 29, pp. 271 - 279, http://dx.doi.org/10.1111/jvh.13658
,2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706
,2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526
,2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103421
,2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', PLoS ONE, 16, http://dx.doi.org/10.1371/journal.pone.0257369
,2021, 'Association between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection among People Who Inject Drugs: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 73, pp. E107 - E118, http://dx.doi.org/10.1093/cid/ciaa612
,2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571
,2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038
,2020, 'Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: A national record-linkage study', Gut, 69, pp. 2223 - 2231, http://dx.doi.org/10.1136/gutjnl-2019-320007
,2020, 'Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C', Liver International, 40, pp. 2353 - 2355, http://dx.doi.org/10.1111/liv.14661
,2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
,2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
,2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
,2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5
,2018, 'Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis', Journal of Viral Hepatitis, 25, pp. 930 - 938, http://dx.doi.org/10.1111/jvh.12897
,2018, 'Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis', Liver International, 38, pp. 1402 - 1410, http://dx.doi.org/10.1111/liv.13681
,2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837
,2018, 'The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen', Journal of Hepatology, 68, pp. 646 - 654, http://dx.doi.org/10.1016/j.jhep.2017.10.033
,2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019
,2018, 'Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era', International Journal of Drug Policy, 52, pp. 115 - 122, http://dx.doi.org/10.1016/j.drugpo.2017.12.014
,2018, 'Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016)', HIV Medicine, 19, pp. 11 - 15, http://dx.doi.org/10.1111/hiv.12599
,2018, 'The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study', Hepatology, 67, pp. 97 - 107, http://dx.doi.org/10.1002/hep.29419
,2018, 'Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis', Journal of Hepatology, 68, pp. S67 - S67, http://dx.doi.org/10.1016/s0168-8278(18)30355-6
,2017, 'Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era', Journal of Viral Hepatitis, 24, pp. 295 - 303, http://dx.doi.org/10.1111/jvh.12646
,2017, 'Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population', Journal of Hepatology, 66, pp. 19 - 27, http://dx.doi.org/10.1016/j.jhep.2016.08.004
,2017, 'Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort', Journal of Hepatology, 66, pp. S22 - S23, http://dx.doi.org/10.1016/s0168-8278(17)30306-9
,2016, 'A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy', Journal of Viral Hepatitis, 23, pp. 1009 - 1016, http://dx.doi.org/10.1111/jvh.12580
,